m6A-induced lncRNA MALAT1 aggravates renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway

被引:100
作者
Liu, Peihua [1 ]
Zhang, Bo [1 ]
Chen, Zhi [1 ]
He, Yao [1 ]
Du, Yongchao [1 ]
Liu, Yuhang [1 ]
Chen, Xiang [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Hunan, Peoples R China
来源
AGING-US | 2020年 / 12卷 / 06期
基金
中国国家自然科学基金;
关键词
renal fibrosis; TGF-beta; 1; MALAT1; dihydroartemisinin; m(6)A; LONG NONCODING RNAS; TO-MESENCHYMAL TRANSITION; TGF-BETA SIGNAL; DIABETIC-NEPHROPATHY; GENE-EXPRESSION; FIBROSIS; PROLIFERATION; CANCER; APOPTOSIS; DISEASE;
D O I
10.18632/aging.102950
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Renal fibrosis is a key factor in chronic kidney disease (CKD). Long non-coding RNAs (lncRNAs) play important roles in the physiological and pathological progression of human diseases. However, the roles and underlying mechanisms of lncRNAs in renal fibrosis still need to be discovered. In this study, we first displayed the increased lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression in renal fibrosis in patients with obstructive nephropathy (ON). Then we found that transforming growth factor beta 1 (TGF-beta 1) induced epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) protein deposition, which promoted the viability, proliferation and migration of human renal proximal tubular epithelial (HK2) cells. Next, MALAT1/miR-145/focal adhesion kinase (FAK) pathway was confirmed to play an importment role in TGF-beta 1-induced renal fibrosis. In addition, the MALAT1/miR-145/FAK pathway was involved in the effect of dihydroartemisinin (DHA) on TGF-beta 1-induced renal fibrosis in vitro and in vivo. Furthermore, m(6)A methyltransferase methyltransferase-like 3 (METTL3) was shown to be the main methyltransferase of m(6)A modification on MALAT1.
引用
收藏
页码:5280 / 5299
页数:20
相关论文
共 55 条
  • [1] Anti-fibrotic treatments: A review of clinical evidence
    Allinovi, Marco
    De Chiara, Letizia
    Angelotti, Maria Lucia
    Becherucci, Francesca
    Romagnani, Paola
    [J]. MATRIX BIOLOGY, 2018, 68-69 : 333 - 354
  • [2] Whole-transcriptome analysis of UUO mouse model of renal fibrosis reveals new molecular players in kidney diseases
    Arvaniti, Eleni
    Moulos, Panagiotis
    Vakrakou, Athina
    Chatziantoniou, Christos
    Chadjichristos, Christos
    Kavvadas, Panagiotis
    Charonis, Aristidis
    Politis, Panagiotis K.
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [3] A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression
    Bernard, Delphine
    Prasanth, Kannanganattu V.
    Tripathi, Vidisha
    Colasse, Sabrina
    Nakamura, Tetsuya
    Xuan, Zhenyu
    Zhang, Michael Q.
    Sedel, Frederic
    Jourdren, Laurent
    Coulpier, Fanny
    Triller, Antoine
    Spector, David L.
    Bessis, Alain
    [J]. EMBO JOURNAL, 2010, 29 (18) : 3082 - 3093
  • [4] Bonventre JV, 2007, CONTRIB NEPHROL, V156, P39
  • [5] TGF-beta in kidney fibrosis: A target for gene therapy
    Border, WA
    Noble, NA
    [J]. KIDNEY INTERNATIONAL, 1997, 51 (05) : 1388 - 1396
  • [6] TGF-β signaling in renal disease
    Böttinger, EP
    Bitzer, M
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10): : 2600 - 2610
  • [7] Overview of the cellular and molecular basis of kidney fibrosis
    Eddy, Allison A.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2014, 4 (01) : 2 - 8
  • [8] Mechanisms of progression of chronic kidney disease
    Fogo, Agnes B.
    [J]. PEDIATRIC NEPHROLOGY, 2007, 22 (12) : 2011 - 2022
  • [9] Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities
    Gajjala, Prathibha Reddy
    Sanati, Maryam
    Jankowski, Joachim
    [J]. FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [10] An integrative view on the role of TGF-β in the progressive tubular deletion associated with chronic kidney disease
    Garcia-Sanchez, Omar
    Lopez-Hernandez, Francisco J.
    Lopez-Novoa, Jose M.
    [J]. KIDNEY INTERNATIONAL, 2010, 77 (11) : 950 - 955